EUVIMEDEUVIMED entdecken
Crossref

Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer

Moein Moradpour, Abuzar Moradi Tuchayi, Surekha Yadav, Fei Jiang, Irene A Burger, Sabin George Pop, Devaki Shilpa Surasi, Akram Hussein, Ishan Arora, Ana Aparicio, Ivan de Kouchkovsky, Robert R Flavell und 1 weitere

Journal of Nuclear Medicine · 2026-05 · 67 (5) · 739-743

DOI: 10.2967/jnumed.125.271296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 05.03.2026. Verfasst von Moein Moradpour und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California. Hauptthemen laut MEDLINE: Antigens, Surface, Glutamate Carboxypeptidase II, Prostatic Neoplasms. Die Arbeit nennt 17 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, SurfaceGlutamate Carboxypeptidase IIProstatic NeoplasmsHumansMaleRetrospective StudiesAgedLigandsMiddle AgedProstate-Specific AntigenTreatment Outcome

Stichwörter der Autor:innen

AVPCPSMA RLTaggressive-variant prostate cancermCRPCoverall survival

Substanzen

Antigens, SurfaceGlutamate Carboxypeptidase IIFOLH1 protein, humanLigandsProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
  • Department of Epidemiology and Biostatistics, University of California, San Francisco, California.
  • Department of Nuclear Medicine, Kantonsspital Baden, Affiliated Hospital for Research and Teaching of the Faculty of Medicine of the University of Zurich, Baden, Switzerland.
  • Department of Nuclear Medicine, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
  • Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
  • Department of Nuclear Medicine, MD Anderson Cancer Center, University of Texas, Houston, Texas.

Förderung

  • NCI NIH HHS

Zitieren

APA

Moradpour, M., Moradi Tuchayi, A., Yadav, S., Jiang, F., Burger, I. A., Pop, S. G., Surasi, D. S., Hussein, A., Arora, I., Aparicio, A., de Kouchkovsky, I., Flavell, R. R., & Hope, T. A. (2026). Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer. Journal of Nuclear Medicine, 67(5), 739-743. https://doi.org/10.2967/jnumed.125.271296

Vancouver

Moradpour M, Moradi Tuchayi A, Yadav S, Jiang F, Burger IA, Pop SG, et al. Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer. Journal of Nuclear Medicine. 2026;67(5):739-743. doi:10.2967/jnumed.125.271296

BibTeX
@article{Moradpour2026,
  author = {Moradpour, Moein and Moradi Tuchayi, Abuzar and Yadav, Surekha and Jiang, Fei and Burger, Irene A and Pop, Sabin George and Surasi, Devaki Shilpa and Hussein, Akram and Arora, Ishan and Aparicio, Ana and de Kouchkovsky, Ivan and Flavell, Robert R and Hope, Thomas A},
  title = {Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {5},
  pages = {739--743},
  doi = {10.2967/jnumed.125.271296}
}
Kostenlos starten →